{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T04:03:21Z","timestamp":1748059401582,"version":"3.41.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2001,1,1]],"date-time":"2001-01-01T00:00:00Z","timestamp":978307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2001,1,1]],"date-time":"2001-01-01T00:00:00Z","timestamp":978307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2001,1]]},"DOI":"10.1023\/a:1009847006280","type":"journal-article","created":{"date-parts":[[2002,12,22]],"date-time":"2002-12-22T23:53:29Z","timestamp":1040601209000},"page":"7-14","source":"Crossref","is-referenced-by-count":12,"title":["Heart Failure Therapy at the Turn of the Century"],"prefix":"10.1007","volume":"6","author":[{"suffix":"MD","given":"S","family":"Goldstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"281744_CR1","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1053\/hj.1999.v137.95495","volume":"137","author":"GA Haldeman","year":"1999","unstructured":"Haldeman GA, Croft JB, Giles WH, Rashidee A. Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. Am Heart J 1999;137:352\u2013360.","journal-title":"Am Heart J"},{"key":"281744_CR2","first-page":"S107","volume":"13","author":"JB O'Connell","year":"1993","unstructured":"O'Connell JB, Bristow M. Economic impact of heart failure in the United States: Time for a different approach. J Heart Lung Transplant 1993;13:S107-S112.","journal-title":"J Heart Lung Transplant"},{"key":"281744_CR3","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/0002-8703(91)90225-7","volume":"121","author":"WB Kannel","year":"1991","unstructured":"Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J 1991;121:951\u2013957.","journal-title":"Am Heart J"},{"key":"#cr-split#-281744_CR4.1","doi-asserted-by":"crossref","unstructured":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators [published erratum appears in N Engl J Med 1992;327:685-691","DOI":"10.1056\/NEJM199209033271003"},{"key":"#cr-split#-281744_CR4.2","doi-asserted-by":"crossref","unstructured":"N Engl J Med 1992, Dec 10;327:1768].","DOI":"10.1056\/NEJM199212103272427"},{"key":"281744_CR5","doi-asserted-by":"crossref","unstructured":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative north Scandinavian Enalapril Survival Study (CONSENSUS). Fig. 6. The patho physiology of heart failure and the role of drug intervention. RSA-renin angiotensin system; ANF\u00e0Atrial Natrivretic Factor. Fig. 7. The incremental change in mortality in patients with heart failure as a result of treatment with ACEI and BB, and their effect on the number of patients needed to treat for one year in order to prevent one death (adapted from McMurray. Heart, 1999; 82: IV 14\u201322.) SOLVD-T [6] and MERITHF \u00e1 CIBIS II [15,16]. 12 Goldstein The CONSENSUS Trial Study Group. N Engl J Med 1987;316:1429\u201335.","DOI":"10.1056\/NEJM198706043162301"},{"key":"281744_CR6","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","author":"SOLVD The","year":"1991","unstructured":"The SOLVD investigators. Effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293\u2013302.","journal-title":"N Engl J Med"},{"key":"281744_CR7","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1161\/01.CIR.82.5.1724","volume":"82","author":"GS Francis","year":"1990","unstructured":"Francis GS, Benedict C, Johnstone DE et al. for the SOLVD Investigators. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. Circulation 1990;82:1124\u20131729.","journal-title":"Circulation"},{"key":"281744_CR8","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0735-1097(84)80044-3","volume":"4","author":"R DiBianco","year":"1984","unstructured":"DiBianco R, Shabetai R, Silverman BD, Leier CV, Benotti JR. Oral amrinone for the treatment of chronic congestive heart failure: Results of a multicenter randomized double-blind and placebocontrolled withdrawal study. J Am Coll Cardiol 1984;4:855\u2013866.","journal-title":"J Am Coll Cardiol"},{"key":"281744_CR9","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/01.CIR.82.3.774","volume":"82","author":"BF Uretsky","year":"1990","unstructured":"Uretsky BF, Jessup M, Konstam MA et al. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group. Circulation 1990;82:774\u2013780.","journal-title":"Circulation"},{"key":"281744_CR10","doi-asserted-by":"crossref","first-page":"113A","DOI":"10.1016\/0735-1097(93)90473-E","volume":"22","author":"WS Colucci","year":"1993","unstructured":"Colucci WS, Sonnenblick EH, Adams KF et al. Efficacy of phosphodiesterase inhibition with milrinone in combination with converting enzyme inhibitors in patients with heart failure. The Milrinone Multicenter trials Investigators. J Am Coll Cardiol 1993;22: 113A-118A.","journal-title":"J Am Coll Cardiol"},{"key":"281744_CR11","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJM199111213252103","volume":"325","author":"M Packer","year":"1991","unstructured":"Packer M, Carver JR, Rodeheffer RJ et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991;325:1468\u20131475.","journal-title":"N Engl J Med"},{"key":"281744_CR12","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJM198606123142404","volume":"314","author":"JN Cohn","year":"1986","unstructured":"Cohn JN, Archibald DG, Ziesche S et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a veterans Administration Cooperative Study. N Engl J Med 1986;314: 1547\u20131552.","journal-title":"N Engl J Med"},{"key":"281744_CR13","first-page":"V178","volume":"87","author":"HS Loeb","year":"1993","unstructured":"Loeb HS, Johnson G, Henrick A et al. Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative studies Group. Circulation 1993;87: V178-V187.","journal-title":"Circulation"},{"key":"281744_CR14","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","volume":"334","author":"M Packer","year":"1996","unstructured":"Packer M, Bristow MR, Cohn JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996;334: 1349\u20131355.","journal-title":"N Engl J Med"},{"key":"281744_CR15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","volume":"353","author":"CIBIS-II Investigators and Committees. The Cardiac Insufficient Bisoprolol Study II (CIBIS-II)","year":"1999","unstructured":"CIBIS-II Investigators and Committees. The Cardiac Insufficient Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999;353:9\u201313.","journal-title":"Lancet"},{"key":"281744_CR16","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","volume":"353","author":"MERIT-HF Study Group.","year":"1999","unstructured":"MERIT-HF Study Group. The effect of metoprolol CR\/XL in chronic heart failure: metoprolol CR\/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353:2001\u20132007.","journal-title":"Lancet"},{"key":"281744_CR17","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1001\/archinte.1994.00420170045004","volume":"154","author":"RJ Cody","year":"1994","unstructured":"Cody RJ, Kubo SH, Pickworth KK. Diuretic treatment for the sodium retention of congestive heart failure. Arch Intern Med 1994;154:1905\u20131914.","journal-title":"Arch Intern Med"},{"key":"281744_CR18","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/0002-9343(81)90755-5","volume":"70","author":"JR Wilson","year":"1981","unstructured":"Wilson JR, Reichek N, Dunkman WB, Golberg S. Effect of diuresis on the performance of the failing left ventricle in man. Am J Med 1981;70:234\u2013239.","journal-title":"Am J Med"},{"key":"281744_CR19","doi-asserted-by":"crossref","first-page":"314","DOI":"10.7326\/0003-4819-102-3-314","volume":"102","author":"MR Vasko","year":"1985","unstructured":"Vasko MR, Cartwright DB, Knochel JP, et al. Furosemide absorption altered in decompensated congestive heart failure. Ann Intern Med 1985;102: 314\u2013318.","journal-title":"Ann Intern Med"},{"key":"281744_CR20","first-page":"656","volume":"21","author":"M Epstein","year":"1977","unstructured":"Epstein M, Lepp BA, Hoffman DS, Levinson R. Potentiation of furosemide by metolazone in refractory edema. Curr Ther Res 1977;21: 656\u2013667.","journal-title":"Curr Ther Res"},{"key":"281744_CR21","doi-asserted-by":"crossref","first-page":"886","DOI":"10.7326\/0003-4819-114-10-886","volume":"114","author":"DH. Ellison","year":"1991","unstructured":"Ellison DH. The physiologic basis of diuretic synergism: Its role in treating diuretic resistance. Ann Intern Med 1991;114:886\u2013894.","journal-title":"Ann Intern Med"},{"key":"281744_CR22","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1161\/01.CIR.96.10.3294","volume":"96","author":"M St. John Sutton","year":"1997","unstructured":"St. John Sutton M, Pfeffer MA, Moy\u00e9 L, et al. for the SAVE Investigators. Cardiovascular death and left ventricular remoldeling two years after myocardial infarction. Baseline predictors and impact of longterm use of captopril: Information from the survival and ventricular enlargement (SAVE) trial. Circulation 1997;96:3294\u20133299.","journal-title":"Circulation"},{"key":"281744_CR23","doi-asserted-by":"crossref","unstructured":"Konstam MA, Rousseau M, Kronenberg MW, Udelson JE, Yusuf S, Pouleur H, for the SOLVD Investigators. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. Circulation 192;86:431\u2013438.","DOI":"10.1161\/01.CIR.86.2.431"},{"key":"281744_CR24","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1136\/hrt.76.3_Suppl_3.33","volume":"76","author":"T Yamazaki","year":"1996","unstructured":"Yamazaki T, Komuro I, Shiojima I, Yazaki Y. The renin-angiotensin system and cardiac hypertrophy. Heart 1996;76:33\u201335.","journal-title":"Heart"},{"key":"281744_CR25","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/cvr\/26.7.671","volume":"26","author":"CG Brilla","year":"1992","unstructured":"Brilla CG, Weber KT, Reaction and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res 1992;26:671\u2013677.","journal-title":"Cardiovasc Res"},{"key":"281744_CR26","doi-asserted-by":"crossref","first-page":"22348","DOI":"10.1016\/S0021-9258(18)45712-2","volume":"265","author":"H Urata","year":"1990","unstructured":"Urata H, Kinoshita A, Misono KS, et al. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990;265:22348\u201322357.","journal-title":"J Biol Chem"},{"key":"281744_CR27","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1161\/01.RES.66.4.883","volume":"66","author":"H Urata","year":"1990","unstructured":"Urata H, Healy B, Stewart RW, et al. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 1990;66:883\u2013890.","journal-title":"Circ Res"},{"key":"281744_CR28","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1172\/JCI109788","volume":"65","author":"SL Swartz","year":"1980","unstructured":"Swartz SL, Williams GH, Hollenberg NK, Levine L, Dluhy RG, Moore TJ. Captopril-induced changes in prostaglandin production: Relationship to vascular responses in normal man. J Clin Invest 1980;65: 1257\u20131264.","journal-title":"J Clin Invest"},{"key":"281744_CR29","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1161\/01.HYP.16.5.564","volume":"16","author":"L Juillerat","year":"1990","unstructured":"Juillerat L, Nussberger J, Menard J et al. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertensin 1990;16:564\u2013572.","journal-title":"Hypertensin"},{"key":"281744_CR30","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","volume":"327","author":"SOLVD The","year":"1992","unstructured":"The SOLVD investigators. Effects of enalpril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685\u2013691.","journal-title":"N Engl J Med"},{"key":"281744_CR31","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","volume":"342","author":"S Yusef","year":"2000","unstructured":"Yusef S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145\u2013153.","journal-title":"N Engl J Med"},{"key":"281744_CR32","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","volume":"100","author":"M Packer","year":"1999","unstructured":"Packer M, Poole-Wilson PA, Armstrong PW et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999;100:2312\u20132318.","journal-title":"Circulation"},{"key":"281744_CR33","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1097\/00004872-198909007-00006","volume":"7","author":"M Burnier","year":"1989","unstructured":"Burnier M, Waeber B, Nussberger J, Brunner HR. Effect of angiotensin converting enyzme inhibition in renovascular hypertensin. J Hypertens Suppl 1989;7:S27-S31.","journal-title":"J Hypertens Suppl"},{"key":"281744_CR34","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1071-9164(99)91340-4","volume":"5","author":"Heart Failure Society of America (HFSA) practice guidelines","year":"1999","unstructured":"Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction\u2013pharmacological approaches. J Card Fail 1999;5:357\u2013382","journal-title":"J Card Fail"},{"key":"281744_CR35","doi-asserted-by":"crossref","unstructured":"A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982;247:1707\u20131714. Heart Failure Therapy 13","DOI":"10.1001\/jama.1982.03320370021023"},{"key":"281744_CR36","doi-asserted-by":"crossref","unstructured":"A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results. JAMA 1983;250:2814\u20132819.","DOI":"10.1001\/jama.1983.03340200048027"},{"key":"281744_CR37","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1161\/01.CIR.73.3.503","volume":"73","author":"K Chadda","year":"1986","unstructured":"Chadda K, Goldstein S, Byington R, Curb JD. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 1986;73:503\u2013510.","journal-title":"Circulation"},{"key":"281744_CR38","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJM198409273111303","volume":"311","author":"JN Cohn","year":"1984","unstructured":"Cohn JN, Levine BT, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma Norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819\u2013823.","journal-title":"N Engl J Med"},{"key":"281744_CR39","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/0735-1097(94)00543-Y","volume":"25","author":"SA Hall","year":"1995","unstructured":"Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol 1995; 25:1154\u20131161.","journal-title":"J Am Coll Cardiol"},{"key":"281744_CR40","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/0735-1097(94)90114-7","volume":"24","author":"EJ Eichorn","year":"1994","unstructured":"Eichorn EJ, Heesch CM, Barnett JH, et al. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: A randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 1994;24:1310\u20131320.","journal-title":"J Am Coll Cardiol"},{"key":"281744_CR41","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/0002-9149(83)90368-5","volume":"51","author":"JL Anderson","year":"1983","unstructured":"Anderson JL, Rodier HE, Green LS. Comparative effects of beta-adrenergic blocking drugs on experimental ventricular fibrillation threshold. Am J Cardiol 1983;51:1196\u20131202.","journal-title":"Am J Cardiol"},{"key":"281744_CR42","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S0735-1097(00)00924-4","volume":"36","author":"HN Sabbah","year":"2000","unstructured":"Sabbah HN, Sharov VG, Todor A, et al. Long-term therapy with metoprolol attenuates cardiomyocyte apoptosis in dogs with heart failure. J Am Cardiol 2000;36:1691\u20131697.","journal-title":"J Am Cardiol"},{"key":"281744_CR43","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1152\/ajplegacy.1972.222.6.1398","volume":"222","author":"J Torretti","year":"1972","unstructured":"Torretti J, Hendler E, Weinstein E, Longnecker RE, Epstein FH. Functional significance of NA-K-ATPase in the kidney: Effects of ouabain inhibition. Am J Physiol 1972;222:1398\u20131405.","journal-title":"Am J Physiol"},{"key":"281744_CR44","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/01.RES.44.1.8","volume":"44","author":"MD. Thames","year":"1979","unstructured":"Thames MD. Acetylstrophanthidin-induced reflex inhibition of canine renal sympathetic nerve activity mediated by cardiac receptors with vagal afferents. Circ Res 1979;44:8\u201315.","journal-title":"Circ Res"},{"key":"281744_CR45","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1161\/01.CIR.80.1.65","volume":"80","author":"DW Ferguson","year":"1989","unstructured":"Ferguson DW, Berg WJ, Sanders JS, Roach PJ, Kempf JS, Kienzle MG. Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings. Circulation 1989;80:65\u201377.","journal-title":"Circulation"},{"key":"281744_CR46","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0002-9343(83)90346-7","volume":"75","author":"AB Covit","year":"1983","unstructured":"Covit AB, Schaer GL, Sealey JE, Laragh JH, Cody RJ. Suppression of the renin-angiotensin system by intravenous digoxin in chronic congestive heart failure. Am J Med 1983;75:445\u2013447.","journal-title":"Am J Med"},{"key":"281744_CR47","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/0735-1097(93)90403-N","volume":"22","author":"BF Uretsky","year":"1993","unstructured":"Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: Results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol 1993;22:955\u2013962.","journal-title":"J Am Coll Cardiol"},{"key":"281744_CR48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199307013290101","volume":"329","author":"M Packer","year":"1993","unstructured":"Packer M, Gheorghiade M, Young JB et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med 1993; 329:1\u20137.","journal-title":"N Engl J Med"},{"key":"281744_CR49","doi-asserted-by":"crossref","unstructured":"The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 1997;336:525\u2013533.","DOI":"10.1056\/NEJM199702203360801"},{"key":"281744_CR50","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1476-5381.1992.tb09054.x","volume":"105","author":"W Linz","year":"1992","unstructured":"Linz W, Scholkens BA. A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol 1992;105:771\u2013772.","journal-title":"Br J Pharmacol"},{"key":"281744_CR51","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1161\/01.CIR.91.7.2043","volume":"91","author":"KM McDonald","year":"1995","unstructured":"McDonald KM, Mock J, D'Aloia A et al. Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. Circulation 1995;91:2043\u20132048.","journal-title":"Circulation"},{"key":"281744_CR52","unstructured":"Pitt B, Poole-Wilson P, Segal R et al. Losartan Heart Failure Survival Study-ELITE II. Circulation 99 A.D.; 100:I-782."},{"key":"281744_CR53","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709\u2013717. 14 Goldstein","journal-title":"N Engl J Med"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1009847006280.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1009847006280\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1009847006280.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T10:47:24Z","timestamp":1747997244000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1009847006280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,1]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,1]]}},"alternative-id":["281744"],"URL":"https:\/\/doi.org\/10.1023\/a:1009847006280","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"type":"print","value":"1382-4147"},{"type":"electronic","value":"1573-7322"}],"subject":[],"published":{"date-parts":[[2001,1]]}}}